IceCure Medical Ltd. (ICCM) Latest Filing Signal

Latest Filing: 20-F  |  Filed Mar 17, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for IceCure Medical Ltd.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, IceCure Medical Ltd.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does IceCure Medical Ltd. actually do?
Answer:
IceCure Medical Ltd. is a commercial-stage medical device company specializing in liquid nitrogen-based cryoablation technology for tumor treatment. Its lead product, the ProSense system, has received FDA marketing authorization for treating low-risk breast cancer in women aged 70 and above. The company also has a next-generation XSense system with 510(k) clearance and is developing an MSense system for multiple tumor treatments. IceCure's cryoablation technology offers a minimally invasive alternative to surgery, with applications in various organs including the breast, lungs, kidneys, and bones. The company has obtained regulatory approvals in 27 countries, including the U.S., Europe, India, Brazil, and China, and is actively pursuing further market expansion and regulatory clearances for its product pipeline.
Question:
What are IceCure Medical Ltd.'s revenue drivers?
Answer:
Revenue is primarily generated from the sale of cryoablation systems (ProSense, IceSense3) and their associated disposable probes and introducers. The company also generates revenue from exclusive distribution rights in Japan.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required